Perceptions of Multicancer Detection Tests Among Primary Care Physicians and Laypersons: A Qualitative Study
Cancer Medicine · 2024
DOI: 10.1002/cam4.70281 ↗Kurz gefasst
Qualitative Studie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Goli Samimi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Physicians, Primary Care, Early Detection of Cancer, Neoplasms, Qualitative Research. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Division of Cancer Prevention, National Cancer Institute.
Abstract (Originalsprache)
Introduction
Multicancer detection tests (MCDs) are blood‐based tests designed to detect multiple cancer types. It is currently unclear whether these cancer screening tests improve mortality. To understand awareness of MCDs among providers and patients, as well as explore how they perceive the benefits, harms, and acceptability of MCDs, we have undertaken a focus group study in primary care physicians (PCPs) and laypersons to explore knowledge, attitudes, and expectations of cancer screening using MCDs.
Methods
We conducted six focus groups with 45 PCP participants and 12 focus groups with 80 layperson participants. Participants were identified via a consumer research firm and found eligible following the completion of a screener survey. Moderators used a semi‐structured guide containing open‐ended questions and prompts to facilitate the discussion. Recordings were transcribed and coded line by line using a codebook developed based on questions and emerging discussion concepts, and emergent themes were identified.
Results
Both PCP and layperson participants felt the that benefits of MCDs included ease of use and potential ability to detect cancers early. However, they felt that additional data is needed to overcome some of the concerns related to MCDs. PCP participants expressed concerns related to lack of practice guidelines, cost of diagnostic follow‐ups, privacy and insurance issues, fear/anxiety related to confirmation of MCD results, and malpractice liability related to perceived false negative test results. Layperson participants expressed concerns related to costs, insurance coverage, and privacy, as well as anxiety over the confirmation of a positive test result.
Conclusions
There is a major need for more rigorous data regarding MCDs to inform the development of guidelines for use as cancer screening tools.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA.
- Office of Research on Women's Health, National Institutes of Health, Bethesda, Maryland, USA.
- Independent Consultant, Human Research Protections and Bioethics, Bethesda, Maryland, USA.
- Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.
- ICF Next, Reston, Virginia, USA.
ORCID-Profile: Goli Samimi
Förderung
- Division of Cancer Prevention, National Cancer Institute
Zitieren
APA
Samimi, G., Temkin, S. M., Weil, C. J., Han, P. K. J., LeeVan, E., Rubinstein, W. S., Swigart, T. M., Caban, S., Dent, K., & Minasian, L. M. (2024). Perceptions of Multicancer Detection Tests Among Primary Care Physicians and Laypersons: A Qualitative Study. Cancer Medicine. https://doi.org/10.1002/cam4.70281
Vancouver
Samimi G, Temkin SM, Weil CJ, Han PKJ, LeeVan E, Rubinstein WS, et al. Perceptions of Multicancer Detection Tests Among Primary Care Physicians and Laypersons: A Qualitative Study. Cancer Medicine. 2024. doi:10.1002/cam4.70281
BibTeX
@article{Samimi2024,
author = {Samimi, Goli and Temkin, Sarah M and Weil, Carol J and Han, Paul K J and LeeVan, Elyse and Rubinstein, Wendy S and Swigart, Tessa M and Caban, Sarah and Dent, Katherine and Minasian, Lori M},
title = {Perceptions of Multicancer Detection Tests Among Primary Care Physicians and Laypersons: A Qualitative Study},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70281}
}
EUVIMED